Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Low-risk Myelodysplastic Syndrome”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT00539695
What this trial is testing

Low Dose IL-2, Hematopoietic Stem Cell Transplantation, IL2 for GVHD

Who this might be right for
Acute Lymphoblastic LeukemiaALLAcute Myelogenous Leukemia+7 more
Baylor College of Medicine 25
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06594965
What this trial is testing

HS-20106 to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes

Who this might be right for
Myelodysplastic SyndromesAnemiaMDS+1 more
Hansoh BioMedical R&D Company 176
Testing effectiveness (Phase 2)Study completedNCT03387475
What this trial is testing

Evaluating Low-dose Deferasirox (DFX) in Patients With Low-risk MDS Resistant or Relapsing After ESA Agents

Who this might be right for
Myelodysplasia
University Hospital, Grenoble 39
Early research (Phase 1)Study completedNCT03358719
What this trial is testing

DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid LeukemiaBlasts 30 Percent or Less of Bone Marrow Nucleated CellsChronic Myelomonocytic Leukemia+3 more
Roswell Park Cancer Institute 8
Testing effectiveness (Phase 2)Ended earlyNCT05568225
What this trial is testing

Etavopivat for the Treatment of Anemia in Patients With Myelodysplastic Syndromes (MDS)

Who this might be right for
Very Low Risk, Low Risk, or Intermediate Risk MDS Per IPSS-R
Forma Therapeutics, Inc. 17
Testing effectiveness (Phase 2)Study completedNCT01178814
What this trial is testing

Revlimid in Transfusion Dependent Patients

Who this might be right for
Myelodysplastic Syndrome
Columbia University 57
Testing effectiveness (Phase 2)Study completedNCT02269280
What this trial is testing

Phase II Decitabine (DAC) Versus Azacitidine (AZA) in Myelodysplastic Syndrome (MDS)

Who this might be right for
Leukemia
M.D. Anderson Cancer Center 185
Large-scale testing (Phase 3)Looking for participantsNCT07422480
What this trial is testing

Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions

Who this might be right for
Myelodysplastic SyndromeAnemia
Takeda 300
Early research (Phase 1)Study completedNCT01736436
What this trial is testing

APG101 in Myelodysplastic Syndrome

Who this might be right for
Myelodysplastic Syndrome
Apogenix GmbH 20
Testing effectiveness (Phase 2)Ended earlyNCT02877082
What this trial is testing

Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients

Who this might be right for
Acute LeukemiaChronic Lymphocytic LeukemiaChronic Myelogenous Leukemia, BCR-ABL1 Positive+9 more
Emory University 5
Testing effectiveness (Phase 2)Study completedNCT01749514
What this trial is testing

Study of Luspatercept for the Treatment of Anemia in Patients With Myelodysplastic Syndrome (MDS) (MK-6143-001)

Who this might be right for
Anemia
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA 116
Testing effectiveness (Phase 2)Study completedNCT01720225
What this trial is testing

Decitabine Versus Azacitidine in Myelodysplastic Syndrome Patients With Low and Intermediate-1 Risk

Who this might be right for
Leukemia
M.D. Anderson Cancer Center 113
Testing effectiveness (Phase 2)Study completedNCT00118352
What this trial is testing

Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer

Who this might be right for
Acute Undifferentiated LeukemiaAdult Acute Lymphoblastic Leukemia in RemissionAdult Acute Myeloid Leukemia in Remission+61 more
Fred Hutchinson Cancer Center 12
Testing effectiveness (Phase 2)Study completedNCT02268383
What this trial is testing

Extension Study to Evaluate Long-Term Effects of Luspatercept in Patients With Myelodysplastic Syndromes (MDS) (A536-05/MK-6143-003)

Who this might be right for
Myelodysplastic Syndromes
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA 75
Testing effectiveness (Phase 2)Study completedNCT02363491
What this trial is testing

A Phase I/II Study of OPN-305 in Second-line Lower Risk Myelodysplastic Syndrome

Who this might be right for
Myelodysplastic Syndrome
Opsona Therapeutics Ltd. 96
Testing effectiveness (Phase 2)Study completedNCT00778375
What this trial is testing

Clofarabine Plus Low-Dose Cytarabine Induction and Decitabine Consolidation in Frontline Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)

Who this might be right for
Acute Myeloid LeukemiaMyelodysplastic Syndrome
M.D. Anderson Cancer Center 122
Early research (Phase 1)Study completedNCT04718844
What this trial is testing

A Study Investigate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Response of SLN124 in Adults With Alpha/Beta-thalassaemia and Very Low- and Low-risk Myelodysplastic Syndrome

Who this might be right for
Non-transfusion-dependent ThalassemiaLow Risk Myelodysplastic SyndromeVery-Low Risk Myelodysplastic Syndrome
Silence Therapeutics plc 44
Testing effectiveness (Phase 2)WithdrawnNCT00960726
What this trial is testing

NOV-002 in Myelodysplastic Syndrome (MDS)

Who this might be right for
LeukemiaMyelodysplastic Syndrome
M.D. Anderson Cancer Center
Testing effectiveness (Phase 2)Study completedNCT00488592
What this trial is testing

Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers

Who this might be right for
Myelodysplastic Syndrome (MDS)Acute Myeloid Leukemia (AML)Chronic Myeloid Leukemia (CML)
National Heart, Lung, and Blood Institute (NHLBI) 10
Large-scale testing (Phase 3)Active Not RecruitingNCT03682536
What this trial is testing

Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Naïve

Who this might be right for
Myelodysplastic Syndromes
Celgene 363
Next Page